Disclosed is a new chemical compound which is an ester formed between bortezomib and malic acid, wherein the ester can optionally be in the form of a pharmaceutically acceptable salt. Disclosed are further pharmaceutical compositions, preferably powders for solution for injection and solutions for injection containing the new ester compound or the pharmaceutically acceptable salts thereof as well as processes for preparing said pharmaceutical compositions.
